April 2012, EASL’s revised CPGs on the Management of Chronic Hepatitis B (originally released in October 2008) now include; modified indications for liver biopsy and treatment for HBeAg-negative patients, new stopping rules for pegylated interferon-alfa therapy, amended recommendations for patients with partial virological response at 12 months of therapy with entecavir (ETV) or tenofovir (TDF), a replacement of the add-on strategy for resistance (better focus on lamivudine resistance) – replaced by a switch strategy, recommendations for less frequent HBV DNA testing under ETV or TDF, and more detailed recommendations for specific subgroups (particularly for HBV & pregnancy and for HBV & immunosuppression).
Please note: Corrigendum to the EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection [Journal of Hepatology 2012; 57: 167-185]